kras g12d inhibitor incb161734
kras g12d inhibitor incb161734: 6 clinical trials tracked.
kras g12d inhibitor incb161734 evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
What is verified about kras g12d inhibitor incb161734, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (6)
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis
Primary endpoint: PK for plasma INCB161734: Cmax
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment
Primary endpoint: PK for plasma INCB161734: Cmax
An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants
Primary endpoint: Total Recovery (Urine + Feces) of the Administered Radioactivity
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
Primary endpoint: Overall Survival (OS)
An Open-Label Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
Primary endpoint: Pharmacokinetics Parameter (PK): Cmax of INCB161734
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)